GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » Cash Conversion Cycle

USNA (Usana Health Sciences) Cash Conversion Cycle : 135.74 (As of Dec. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Usana Health Sciences's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.
Usana Health Sciences's Days Inventory for the three months ended in Dec. 2024 was 158.25.
Usana Health Sciences's Days Payable for the three months ended in Dec. 2024 was 22.51.
Therefore, Usana Health Sciences's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2024 was 135.74.


Usana Health Sciences Cash Conversion Cycle Historical Data

The historical data trend for Usana Health Sciences's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Usana Health Sciences Cash Conversion Cycle Chart

Usana Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.07 131.36 132.58 110.96 123.54

Usana Health Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.12 110.16 121.93 130.32 135.74

Competitive Comparison of Usana Health Sciences's Cash Conversion Cycle

For the Packaged Foods subindustry, Usana Health Sciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Usana Health Sciences's Cash Conversion Cycle Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Usana Health Sciences's Cash Conversion Cycle falls into.



Usana Health Sciences Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Usana Health Sciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+148.51-24.97
=123.54

Usana Health Sciences's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+158.25-22.51
=135.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Usana Health Sciences  (NYSE:USNA) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Usana Health Sciences Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Usana Health Sciences Business Description

Traded in Other Exchanges
Address
3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Executives
Brent Neidig officer: CO & Man. Dir. of China 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
Joshua Foukas officer: Chief Legal Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
John Turman Fleming director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
David Mulham Mulham officer: Chief Field Development Office 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Gilbert A Fuller officer: CFO and Executive V.P. 55 WANDERWOOD WAY, SANDY UT 84092
Jim Brown officer: Chief Production Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Peggie Pelosi director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84111
Paul A. Jones officer: CFO 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Myron W Wentz director 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
G Doug Iiekking officer: VP of Finance C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Daniel A. Macuga officer: Chief Communications Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Kevin Guest officer: E.V.P. of Marketing 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Walter Noot officer: Chief Information Officer 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Robert A Sinnott officer: Chief Scientific Officer 400 55 WATER STREET, VANCOUVER A1 V6B1A1
Frederic J Winssinger director 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018